European Commission Approves Oral Rolapitant for CINV

April 26, 2017 – The European Commission has approved oral rolapitant tablets for the treatment of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. The approval applies to all 28 EU member states as well as in the European Economic Area (EEA) countries of Iceland, Lichtenstein and Norway. Tesaro, the drug’s manufacturer, plans to begin introducing rolapitant on a country-by-country basis by the end of June. The FDA approved … (leggi tutto)